26187-18-8

Basic information

• Product Name: 2-chloro-N-(1,1-dimethyl-2-phenylethyl)acetamide
• CAS NO: 26187-18-8
• Molecular Formula: C₁₂H₁₆ClNO
• Molecular Weight: 225.7145
• Mol File: 26187-18-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 385.2°C at 760 mmHg
• Flash Point: 186.8°C
• Density: 1.097g/cm³
• Vapor Pressure: 3.86E-06mmHg at 25°C
• Refractive Index: 1.522
• CAS DataBase Reference: 2-chloro-N-(1,1-dimethyl-2-phenylethyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-(1,1-dimethyl-2-phenylethyl)acetamide(26187-18-8)
• EPA Substance Registry System: 2-chloro-N-(1,1-dimethyl-2-phenylethyl)acetamide(26187-18-8)

Safety Data

• Hazardous Substances Data: 26187-18-8(Hazardous Substances Data)

Usage

General Description

2-chloro-N-(1,1-dimethyl-2-phenylethyl)acetamide is a chemical compound that contains chloro, phenyl, dimethyl, and acetamide groups. Its systematic name reveals its structural features, including a chlorine atom attached to a carbon atom, a phenyl ring, two methyl groups, and an acetamide functional group. In its pure form, this substance is likely to appear as a solid due to the characteristics of similar organic compounds. As an amide, it may participate in chemical reactions characteristic to this class of compounds. Due to its complex structure, it's likely to be synthesized for specialized uses in industrial or laboratory settings, such as in the production of pharmaceuticals or polymers, or as an intermediate in organic synthesis. Its specific properties, including toxicity and potential applications, depend on more detailed information and empirical study.

Upstream product

• 79-04-9 chloroacetyl chloride 
• 122-09-8 Phentermin 
• 103-82-2 phenylacetic acid 
• 100-86-7 2-Methyl-1-phenyl-2-propanol 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 110437-16-6 N-methyl-N-(1-methyl-hexyl)-glycine-(1,1-dimethyl-2-phenyl-ethylamide) 
• 82408-64-8 N-(1,1-dimethyl-2-(4-nitrophenyl)ethyl)amine 
• 1274572-31-4 C₁₇H₁₈N₂O₆ 
• 122-09-8 Phentermin 
• 126-27-2 oxethazaine 

Relevant articles and documents

Preparation of Substituted Tetrahydroisoquinolines by Pd(II)-Catalyzed NH2-Directed Insertion of Michael Acceptors into C-H Bonds Followed by NH2-Conjugated Addition

3,3-Disubstituted tetrahydroisoquinolines are prepared in one step from Michael acceptors and 2-phenylethylamines under Pd catalysis and Ag2CO3 as an oxidant. Presumably, activation of an ortho C-H bond of the aromatic ring with Pd(II) is directed by the primary amine to form a palladacycle. Insertion of the olefin, subsequent conjugated addition of the amine, and reductive elimination of Pd(0) affords the expected products. Silver carbonate is not necessary when 2-phenylethylamines are converted previously to N-benzoyloxy-2-phenylethylamines.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Substituted 1-(aminomethyl)-2-(arylacetyl)-1,2,3,4- tetrahydroisoquinolines: A novel class of very potent antinociceptive agents with varying degrees of selectivity for κ and μ opioid receptors

This study describes the synthesis of a series of novel substituted 1- (aminomethyl)-2-(arylacetyl)-1,2,3,4-tetrahydroisoquinolines, and discusses their structure-activity relationships (SARs) using binding affinity for opioid receptors and antinociceptive potency as the indices of biological activity. The introduction of a hydroxy substituent in position 5 of the isoquinoline nucleus generated a compound, 40, which is 2 times more potent than the previously disclosed unsubstituted analogue 39 in mouse models of antinociception. A QSAR analysis of the 5-substitution clearly demonstrates that antinociceptive activity is inversely associated with the lipophilicity of the substituents. The substituted compounds described herein are less selective for the κ opioid receptors than the unsubstituted isoquinoline 39. For example, the 5-hydroxy-substituted compound 59 shows high affinity for κ opioid receptors (K(i) κ = 0.09 nM) and a (K(i) μ/K(i) κ ratio of only 5. However, a multiple linear regression analysis demonstrates a lack of correlation between antinociceptive activity and affinity for the μ opioid receptor. On the other hand, the correlation between binding affinity to κ opioid receptor and antinociceptive activity was statistically significant.